Related references
Note: Only part of the references are listed.Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology
Chichi Huang
CURRENT OPINION IN BIOTECHNOLOGY (2009)
Incretin-based therapies for type 2 diabetes mellitus
Julie A. Lovshin et al.
NATURE REVIEWS ENDOCRINOLOGY (2009)
Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis
Kristen M. Picha et al.
DIABETES (2008)
Rapid platelet turnover in WASP(-) mice correlates with increased ex vivo phagocytosis of opsonized WASP(-) platelets
Amanda Prislovsky et al.
EXPERIMENTAL HEMATOLOGY (2008)
In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes
N. Soltani et al.
GENE THERAPY (2007)
Caveolin-1 regulates cellular trafficking and function of the glucagon-like peptide 1 receptor
Colin A. Syme et al.
MOLECULAR ENDOCRINOLOGY (2006)
Monomeric Fc fusions - Impact on pharmacokinetic and biological activity of protein therapeutics
Jennifer A. Dumont et al.
BIODRUGS (2006)
Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia
ME Patti et al.
DIABETOLOGIA (2005)
Glucagon-like peptide 1(GLP-1) in biology and pathology
JJ Meier et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Characterization of glucagon-like peptide-1 receptor β-arrestin 2 interaction:: A high-affinity receptor phenotype
R Jorgensen et al.
MOLECULAR ENDOCRINOLOGY (2005)
Fc receptors and their role in immune regulation and autoimmunity
T Takai
JOURNAL OF CLINICAL IMMUNOLOGY (2005)
Synthesis and receptor binding of IgG1 peptides derived from the IgG Fc region
K Uray et al.
JOURNAL OF MOLECULAR RECOGNITION (2004)
Human antibody - Fc receptor interactions illuminated by crystal structures
JM Woof et al.
NATURE REVIEWS IMMUNOLOGY (2004)
A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis
LL Baggio et al.
DIABETES (2004)
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
JJ Holst et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
Growth hormone antibodies formation in patients treated with recombinant human growth hormone
G Ahangari et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2004)
Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis
YZ Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
G-protein-coupled receptor oligomerization and its potential for drug discovery
SR George et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice
Q Wang et al.
DIABETOLOGIA (2002)
Formatting antibody fragments to mediate specific therapeutic functions
ANC Weir et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2002)
Interaction sites on human IgG-Fc for FcγR:: current models
R Jefferis et al.
IMMUNOLOGY LETTERS (2002)
Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases
MEF Melo et al.
JOURNAL OF IMMUNOLOGY (2002)
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes:: a parallel-group study
M Zander et al.
LANCET (2002)
Insulin-induced drug eruptions and reliability of skin tests
AY Lee et al.
ACTA DERMATO-VENEREOLOGICA (2002)
Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report
BM Kumpel et al.
TRANSFUSION CLINIQUE ET BIOLOGIQUE (2002)
Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment
J Larsen et al.
DIABETES CARE (2001)
Share Paper
